1 / 70

Focus on Coronary Artery Disease and Acute Coronary Syndrome

Focus on Coronary Artery Disease and Acute Coronary Syndrome. (Relates to Chapter 34, “Nursing Management: Coronary Artery Disease and Acute Coronary Syndrome,” in the textbook). Coronary Artery Disease and Acute Coronary Syndrome.

dieter
Télécharger la présentation

Focus on Coronary Artery Disease and Acute Coronary Syndrome

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript


  1. Focus onCoronary Artery Disease and Acute Coronary Syndrome (Relates to Chapter 34, “Nursing Management: Coronary Artery Disease and Acute Coronary Syndrome,” in the textbook)

  2. Coronary Artery Disease and Acute Coronary Syndrome • A type of blood vessel disorder that is included in the general category of atherosclerosis • Begins as soft deposits of fat that harden with age • Referred to as “hardening of arteries”

  3. Coronary Artery Disease and Acute Coronary Syndrome (Cont’d) • Cardiovascular diseases are the major cause of death in the United States • Heart attacks are still the leading cause of all cardiovascular disease deaths and deaths in general

  4. Coronary Artery Disease Etiology and Pathophysiology • Atherosclerosis is the major cause of CAD • Characterized by a focal deposit of cholesterol and lipid, primarily within the intimal wall of the artery • Endothelial lining altered as a result of inflammation and injury

  5. Risk Factors for CAD • Risk factors can be categorized as • Nonmodifiable risk factors • Age • Gender • Ethnicity • Family history • Genetic predisposition

  6. Risk Factors for CAD (Cont’d) • Risk factors can be categorized as • Modifiable risk factors • Elevated serum lipids • Hypertension • Tobacco use • Physical inactivity • Obesity • Diabetes • Metabolic syndrome • Psychologic states

  7. Risk Factors for CADHealth Promotion • Identification of people at high risk • Health history, including use of prescription/nonprescription medications • Presence of cardiovascular symptoms • Examples??? • Environmental patterns: diet, activity • Values and beliefs about health and illness • Why is this important?

  8. Risk Factors for CADHealth Promotion (Cont’d) • Health-promoting behaviors • Physical fitness • 30 minutes >5 days/week • Regular physical activity contributes to: • Weight reduction • Reduction of >10% in systolic BP • In some men more than women, an increase in HDL cholesterol

  9. Risk Factors for CADHealth Promotion (Cont’d) • Health-promoting behaviors • Nutritional therapy • ↓saturated fats • ↓cholesterol • ↑monounsaturated fats • Nuts, olive oil • ↑omega-3 fatty acids • ↑fruit and whole grains

  10. Risk Factors for CADHealth Promotion (Cont’d) • Health-promoting behaviors • Cholesterol-lowering drug therapy • Drugs that restrict lipoprotein production: Statins, niacin • Drugs that increase lipoprotein removal: Bile acid sequestrants • Drugs that decrease cholesterol absorption: Ezetimibe (Zetia)

  11. Cholesterol-lowering drug therapy • Statins • Serious side effects • Liver damage • Myopathy • Rhabdomyolysis

  12. Cholesterol-lowering drug therapy • Nicotinic acid (niacin) • Flushing • Administer ASA 30-60 prior • GI disturbances • N/V/D

  13. Cholesterol-lowering drug therapy • Bile acid sequestrants • GI disturbances • Bloating • Constipation • Dyspepsia • May interfere with absorption of other medications • Separate administration times

  14. Risk Factors for CADHealth Promotion (Cont’d) • Health-promoting behaviors • Antiplatelet therapy • Aspirin • Inhibits activity of thromboxane A2 • Suppresses platelet aggregation • Clopidogrel (Plavix)

  15. Gerontologic Considerations • Strategies to reduce risk factors are effective but often underprescribed • Necessary to modify guidelines for physical activity • Two points when elderly may consider lifestyle change(s) • When hospitalized • When symptoms result from CAD and not normal aging

  16. Clinical Manifestations of CAD Chronic Stable Angina (Cont’d) • Intermittent chest pain that occurs over a long period with the same pattern of onset, duration, and intensity of symptoms

  17. Clinical Manifestations of CAD Chronic Stable Angina • Etiology and pathophysiology • Reversible (temporary) myocardial ischemia = angina (chest pain) • O2 demand > O2 supply

  18. Clinical Manifestations of CAD Chronic Stable Angina (Cont’d) • Etiology and pathophysiology • Primary reason for insufficient blood flow is narrowing of coronary arteries by atherosclerosis • For ischemia to occur, the artery is usually 75% or more stenosed

  19. Clinical Manifestations of CAD Chronic Stable Angina (Cont’d) • Pain usually lasts 3 to 5 minutes • Subsides when the precipitating factor is relieved • Pain at rest is unusual • ECG reveals ST segment depression

  20. Chronic Stable Angina Types of Angina • Silent ischemia • Up to 80% of patients with myocardial ischemia are asymptomatic • Associated with diabetes mellitus and hypertension • Confirmed by ECG changes

  21. Chronic Stable AnginaTypes of Angina (Cont’d) • Prinzmetal’s (variant) angina • Occurs at rest usually in response to spasm of major coronary artery • Seen in patients with a history of migraine headaches and Raynaud’s phenomenon • Spasm may occur in the absence of CAD

  22. Chronic Stable Angina Nursing and Collaborative Management • Drug therapy: Goal: ↓ O2 demand and/or ↑ O2 supply • Short-acting nitrates: Sublingual • Long-acting nitrates • Nitroglycerin ointment • Transdermal controlled-release nitroglycerin

  23. Chronic Stable Angina Nursing and Collaborative Management (Cont’d) • Drug therapy: Goal: ↓ O2 demand and/or ↑ O2 supply • β-Adrenergic blockers • Calcium channel blockers • If β-adrenergic blockers are poorly tolerated, contraindicated, or do not control anginal symptoms • Used to manage Prinzmetal’s angina • Angiotensin-converting enzyme inhibitors

  24. Chronic Stable AnginaNursing and Collaborative Management (Cont’d) • Diagnostic studies • Health history/physical examination • Laboratory studies • 12-lead ECG • Chest x-ray • Echocardiogram • Exercise stress test

  25. Chronic Stable AnginaNursing and Collaborative Management (Cont’d) • Diagnostic studies • Cardiac catheterization • Diagnostic • Coronary revascularization: Percutaneous coronary intervention • Balloon angioplasty • Stent

  26. Placement of aCoronary Artery Stent Fig. 34-9

  27. Pre- and Post-PCIwith Stent Placement Fig. 34-10

  28. Acute Coronary Syndrome • When ischemia is prolonged and not immediately reversible, acute coronary syndrome (ACS) develops • ACS encompasses: • Unstable angina (UA) • Non–ST-segment-elevation myocardial infarction (NSTEMI) • ST-segment-elevation myocardial infraction (STEMI)

  29. Relationship Between CAD, Chronic Stable Angina, and ACS Fig. 34-11

  30. Clinical Manifestations of ACS Unstable Angina • Unstable angina • New in onset • Occurs at rest • Has a worsening pattern • UA is unpredictable and represents a medical emergency

  31. Clinical Manifestations of ACS Myocardial Infarction (MI) • Result of sustained ischemia (>20 minutes), causing irreversible myocardial cell death (necrosis) • Necrosis of entire thickness of myocardium takes 4 to 6 hours

  32. Acute Myocardial Infarction Fig. 34-13

  33. Clinical Manifestations of ACS Myocardial Infarction • The degree of altered function depends on the area of the heart involved and the size of the infarct • Contractile function of the heart is disrupted in areas of myocardial necrosis • Most MIs involve the left ventricle (LV)

  34. Clinical Manifestations of ACS Myocardial Infarction • Pain • Total occlusion → anaerobic metabolism and lactic acid accumulation → severe, immobilizing chest pain not relieved by rest, position change, or nitrate administration

  35. Clinical Manifestations of ACS Myocardial Infarction (Cont’d) • Pain • Described as heaviness, constriction, tightness, burning, pressure, or crushing • Common locations: substernal, retrosternal, or epigastric areas; pain may radiate

  36. Possible Location of Chest Pain Fig. 34-7

  37. Clinical Manifestations of ACS Myocardial Infarction (Cont’d) • Sympathetic nervous system stimulation results in • Release of glycogen • Diaphoresis • Vasoconstriction of peripheral blood vessels • Skin: ashen, clammy, and/or cool to touch

  38. Clinical Manifestations of ACS Myocardial Infarction (Cont’d) • Cardiovascular • Initially, ↑ HR and BP, then ↓ BP (secondary to ↓ in CO) • Crackles • Jugular venous distention • Abnormal heart sounds • S3 or S4 • New murmur

  39. Clinical Manifestations of ACS Myocardial Infarction (Cont’d) • Nausea and vomiting • Can result from reflex stimulation of the vomiting center by the severe pain • Fever • Systemic manifestation of the inflammatory process caused by cell death

  40. Complications of Myocardial Infarction • Dysrhythmias • Most common complication • Present in 80% of MI patients • Most common cause of death in the prehospital period • Life-threatening dysrhythmias seen most often with anterior MI, heart failure, or shock

  41. Complications of Myocardial Infarction (Cont’d) • Heart failure • A complication that occurs when the pumping power of the heart has diminished

  42. Complications of Myocardial Infarction (Cont’d) • Cardiogenic shock • Occurs when inadequate oxygen and nutrients are supplied to the tissues because of severe LV failure • Requires aggressive management

  43. Complications of Myocardial Infarction (Cont’d) • Papillary muscle dysfunction • Causes mitral valve regurgitation • Condition aggravates an already compromised LV • Ventricular aneurysm • Results when the infarcted myocardial wall becomes thinned and bulges out during contraction

  44. Complications of Myocardial Infarction (Cont’d) • Acute pericarditis • An inflammation of visceral and/or parietal pericardium • May result in cardiac compression, ↓ LV filling and emptying, heart failure • Pericardial friction rub may be heard on auscultation • Chest pain different from MI pain • Worse when recumbent • Improves when leaning forward

  45. Acute pericarditis

  46. Diagnostic Studies Unstable Angina and Myocardial Infarction • Detailed health history and physical • 12-lead ECG: Changes in QRS complex, ST segment, and T wave can rule out or confirm UA or MI • Serum cardiac markers • Coronary angiography • Others: Exercise stress testing, echocardiogram

  47. Collaborative CareAcute Coronary Syndrome • Emergency management • Initial interventions • ECG • MONA • Ongoing monitoring • Emergent PCI • Treatment of choice for confirmed MI • Balloon angioplasty + drug-eluting stent(s) • Ambulatory 24 hours after the procedure

  48. Collaborative CareAcute Coronary Syndrome (Cont’d) • Fibrinolytic therapy • Indications and contraindications • Read these on your own • Marker of reperfusion: Return of ST segment to baseline • Rescue PCI if thrombolysis fails • Major complication: Bleeding

  49. Collaborative CareAcute Coronary Syndrome (Cont’d) • Drug therapy • IV nitroglycerin • Morphine sulfate • β-adrenergic blockers • Angiotensin-converting enzyme inhibitors • Antidysrhythmia drugs • Cholesterol-lowering drugs • Stool softeners

  50. Collaborative CareAcute Coronary Syndrome (Cont’d) • Nutritional therapy • Progress diet to • Low-salt • Low-saturated fat • Low-cholesterol

More Related